Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

8.960 +0.190 (+2.17%)
Official Closing Price Updated: 4:10 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
(EBS) - Analyzing Emergent BioSolutions's Short Interest
Via Benzinga
7 Analysts Assess Emergent BioSolutions: What You Need To Know
Via Benzinga
What's Going On With Emergent BioSolutions Stock Wednesday?
Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility. 
Via Benzinga
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded use, and updates its 2024 revenue forecast while beating Q2 sales estimates. 
Via Benzinga
Exposures Product Safety
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company 
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine
Emergent BioSolutions stock jumped early Friday. 
Via Investor's Business Daily
Exposures Product Safety
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human... 
Via Benzinga
Exposures Product Safety
Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
From Emergent BioSolutions
Via GlobeNewswire
WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'
To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan. 
Via Benzinga
Macy's Reports Weak Sales, Joins JD.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
From Emergent BioSolutions
Via GlobeNewswire
3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge
Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains. 
Via Talk Markets
Why Emergent BioSolutions Stock Is Skyrocketing Today
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump. 
Via The Motley Fool
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.